Abstract: The invention provides compounds (Ia), (Ib) and (Ic), pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of the Peroxisome Proliferator-Activated Receptor (PPAR) families.

Abstract: Described herein are compounds that include a diarylamine structural feature. Also described herein are methods for making such compounds, methods for using such compounds to modulate the activity of c-kit receptors, and pharmaceutical compositions and medicaments comprising such compounds. Also described herein are methods of using such compounds, pharmaceutical compositions and medicaments to treat and/or prevent and/or inhibit and/or ameliorate the pathology and/or symptomology diseases or conditions associated with the activity of c-kit receptors.

Abstract: Disclosed are nanoparticles, such as carbon nanotubes or other materials having extended aromatic surfaces (e.g., graphene sheet or nanotube), which are used to deliver active agents such as drugs, labels or dyes (termed for convenience a “drug”) to the interior of cells. The nanoparticles are functionalized by a hydrophilic polymer to render them stable in suspension. This molecule may be covalently attached to the nanoparticle, or may be adsorbed thereto as an amphiphilic molecule. The nanoparticles are coupled to the drug through supramolecular bonding i.e., binding to the exterior of the nanoparticle through ?-stacking. The drug may also be covalently bonded to the hydrophilic polymer, which is coupled to the nanoparticle through supramolecular bonding. The drug is therefore capable of release in the cell exterior. The drug is more rapidly released at lower pH, as found e.g., in tumor cells.

Abstract: The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of liver X receptors (LXRs).

Abstract: Described herein are compounds that include a diarylamine structural feature. Also described herein are methods for making such compounds, methods for using such compounds to modulate the activity of c-kit receptors, and pharmaceutical compositions and medicaments comprising such compounds. Also described herein are methods of using such compounds, pharmaceutical compositions and medicaments to treat and/or prevent and/or inhibit and/or ameliorate the pathology and/or symptomology diseases or conditions associated with the activity of c-kit receptors.

Abstract: A method for updating the return on investment (ROI) templates used by business consultants. The present invention comprises a Template Evaluation Program (TEP) and a Template Analysis Program (TAP). The TEP compares the default template to the templates modified by the consultants for the customer's ROI analysis and assigns an effectiveness factor to the modified templates. The TAP develops a data list from the default templates and the effectiveness factors and plots the data on a histogram. The TAP performs a statistical analysis for each parameter and updates the default template parameter values if the data fits a normal distribution curve. If the data forms more than one peak on the histogram, then the TAP uses one peak to update the default template and uses the second peak to create a new template. The new template's parameter value is derived from the data in the second peak.

Abstract: A method for utilizing the Monte Carlo method to determine the most efficient arrangement of schedulers for a grid using a Scheduler Optimization Program (SOP). The SOP obtains the schedulers and scheduler timetable from memory and randomly selects a time period and scheduler to analyze. The SOP then uses the selected scheduler to modify the scheduler timetable. The SOP then runs the ROI calculator to obtain a ROI property for the modified timetable. If the ROI property for the modified timetable is greater than the ROI property for the original scheduler timetable, the SOP replaces the scheduler timetable with the modified timetable.

Abstract: The invention provides compounds and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of c-kit, PDGFR?, PDGFR?, CSF1R, Abl, BCR-Abl, CSK, JNK1, JNK2, p38, p70S6K, TGF?, SRC, EGFR, trkB, FGFR3, FLT3, Fes, Lck, Syk, RAF, MKK4, MKK6, SAPK2?, BRK, KDR, c-raf or b-raf kinase, or mutant forms thereof.

Abstract: Described herein are compounds that include a diarylamine structural feature. Also described herein are methods for making such compounds, methods for using such compounds to modulate the activity of c-kit receptors, and pharmaceutical compositions and medicaments comprising such compounds. Also described herein are methods of using such compounds, pharmaceutical compositions and medicaments to treat and/or prevent and/or inhibit and/or ameliorate the pathology and/or symptomology diseases or conditions associated with the activity of c-kit receptors.

Abstract: Described herein are compounds that include a diarylamine structural feature. Also described herein are methods for making such compounds, methods for using such compounds to modulate the activity of c-kit receptors, and pharmaceutical compositions and medicaments comprising such compounds. Also described herein are methods of using such compounds, pharmaceutical compositions and medicaments to treat and/or prevent and/or inhibit and/or ameliorate the pathology and/or symptomology diseases or conditions associated with the activity of c-kit receptors.

Abstract: Described herein are compounds that include a diarylamine structural feature. Also described herein are methods for making such compounds, methods for using such compounds to modulate the activity of c-kit receptors, and pharmaceutical compositions and medicaments comprising such compounds. Also described herein are methods of using such compounds, pharmaceutical compositions and medicaments to treat and/or prevent and/or inhibit and/or ameliorate the pathology and/or symptomology diseases or conditions associated with the activity of c-kit receptors.

Abstract: The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of liver X receptors (LXRs).

Abstract: Described herein are compounds that include a diarylamine structural feature. Also described herein are methods for making such compounds, methods for using such compounds to modulate the activity of c-kit receptors, and pharmaceutical compositions and medicaments comprising such compounds. Also described herein are methods of using such compounds, pharmaceutical compositions and medicaments to treat and/or prevent and/or inhibit and/or ameliorate the pathology and/or symptomology diseases or conditions associated with the activity of c-kit receptors.

Abstract: The present invention provides for a method for software development. A first computer program code written in a programming language is received for analysis. The first computer program code is analyzed for at least a programming error. If at least one programming error is found, correction suggestions are generated based on the detected programming error. The correction suggestions are displayed to a user for input from the user. The first computer program code is modified in response to the user input.

Abstract: A method for utilizing the Monte Carlo method to determine the most efficient arrangement of schedulers for a grid using a Scheduler Optimization Program (SOP). The SOP obtains the schedulers and scheduler timetable from memory and randomly selects a time period and scheduler to analyze. The SOP then uses the selected scheduler to modify the scheduler timetable. The SOP then runs the ROI calculator to obtain a ROI property for the modified timetable. If the ROI property for the modified timetable is greater than the ROI property for the original scheduler timetable, the SOP replaces the scheduler timetable with the modified timetable.

Abstract: A method to control the distribution of the starch sugar's molecular weight by controlling of Ultra-low DE value during the reaction was invented. The method comprising blending starch with water to get starch slurry, and then mixing it with the 0.01%-0.03% of CaCl2 based on dried starch. The next step involves adjusting the pH of the starch slurry. A further step involves adding 0.03%-0.08% of heat-resisting ?-amylases based on dried starch to the starch slurry described above. A further step involves controlling the production under optimal reaction conditions.

Abstract: A method for removal of the monosaccharide in oligosaccharides production which includes the step of culturing the yeast. A further step involves mixing 8%-12% (W/W) of yeast based on the weight of oligosaccharides and 0.1%-0.5% (W/W) of carbamide as nitrogen source with raw oligosaccharide syrup, and then adjusting the pH value to 4.5-6.0. A further step involves culturing the above oligosaccharides syrup at 23° C.-26° C. for 20-30 hours with intermittent agitation.

Abstract: A method for updating the return on investment (ROI) templates used by business consultants. The present invention comprises a Template Evaluation Program (TEP) and a Template Analysis Program (TAP). The TEP compares the default template to the templates modified by the consultants for the customer's ROI analysis and assigns an effectiveness factor to the modified templates. The TAP develops a data list from the default templates and the effectiveness factors and plots the data on a histogram. The TAP performs a statistical analysis for each parameter and updates the default template parameter values if the data fits a normal distribution curve. If the data forms more than one peak on the histogram, then the TAP uses one peak to update the default template and uses the second peak to create a new template. The new template's parameter value is derived from the data in the second peak.